Disclosure Information

Financial Disclosure and Conflicts:
Humacyte Chief Executive and Chief Medical Officer: Salary, Stock Options and (past) Research Funding

Disclaimer:
The Humacyte investigational bioengineered vessel and is currently being studied in Poland and the US to evaluate its potential safety and preliminary efficacy when used as a vascular access in patients with End Stage Renal Disease requiring hemodialysis and in patients with Peripheral Arterial Disease.

This investigational product has not been submitted for regulatory approval by the FDA or any other regulatory authority. Both the clinical significance of the data reviewed in this presentation, and any potential future indication(s), warnings, precautions, and adverse reactions are unknown at this time.

This presentation includes unpublished data as of November, 2018.

Polymer scaffold is designed to guide tissue shape ...

... and designed to degrade ...

Production of Investigational Bioengineered Vessels

Human Vascular Cells Isolated, Screened, Banked

Bioengineered Vessel: 6mm in diameter, 40cm in length

Collagen I

Collagen III

Vitronectin

Fibronectin
6mm diameter, 40cm length

<table>
<thead>
<tr>
<th>Bioengineered Blood Vessels</th>
<th>Suture Strength (g)</th>
<th>Burst Pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>582 ± 38 (14)</td>
<td>2337 ± 243 (144)</td>
</tr>
<tr>
<td>Human saphenous vein</td>
<td>195 ± 20 (5)</td>
<td>1599 ± 832 (1)</td>
</tr>
<tr>
<td>Human internal mammary artery</td>
<td>148 ± 90 (36)</td>
<td>3195 ± 1265 (148)</td>
</tr>
</tbody>
</table>


Animal Explant

Superior HUMACYL™ Durable Patency

Evidence of Repopulation

Evidence of Healing

CONFIDENTIAL
Phase 2 Studies for Arterial Bypass

Off-the-shelf bioengineered vascular tissues are possible.
- Non immunogenic, integrate with native tissue, repopulate and remodel
- Post implant with increased strength and are durable
- Phase II clinical trial are complete for hemodialysis access and PAD
- Global Phase III clinical trial in hemodialysis access has just closed and a number of vascular programs are in development